0000899243-22-032236.txt : 20220929
0000899243-22-032236.hdr.sgml : 20220929
20220929160516
ACCESSION NUMBER: 0000899243-22-032236
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220927
FILED AS OF DATE: 20220929
DATE AS OF CHANGE: 20220929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Michaelson Jennifer
CENTRAL INDEX KEY: 0001838061
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 221280553
MAIL ADDRESS:
STREET 1: C/O CULLINAN MANAGEMENT, INC.
STREET 2: ONE MAIN STREET SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Oncology, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-27
0
0001789972
Cullinan Oncology, Inc.
CGEM
0001838061
Michaelson Jennifer
C/O CULLINAN ONCOLOGY, INC.
ONE MAIN STREET, SUITE 520
CAMBRIDGE
MA
02142
0
1
0
0
See Remarks
Common Stock
2022-09-27
4
M
0
4000
4.30
A
57031
D
Common Stock
2022-09-27
4
S
0
4000
12.40
D
53031
D
Stock Option (Right to Buy)
4.30
2022-09-27
4
M
0
4000
0.00
D
2030-10-28
Common Stock
4000
204593
D
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.56. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Chief Development Officer, Biologics
/s/ Jeffrey Trigilio, Attorney-in-Fact
2022-09-29